254 related articles for article (PubMed ID: 19690028)
1. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.
Wiseman GA; Pacak K; O'Dorisio MS; Neumann DR; Waxman AD; Mankoff DA; Heiba SI; Serafini AN; Tumeh SS; Khutoryansky N; Jacobson AF
J Nucl Med; 2009 Sep; 50(9):1448-54. PubMed ID: 19690028
[TBL] [Abstract][Full Text] [Related]
2. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
[TBL] [Abstract][Full Text] [Related]
3. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
4. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
5. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.
Fukuoka M; Taki J; Mochizuki T; Kinuya S
Clin Nucl Med; 2011 Jan; 36(1):1-7. PubMed ID: 21157198
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma.
Nakamoto R; Nakamoto Y; Ishimori T; Togashi K
Clin Nucl Med; 2016 Nov; 41(11):e465-e472. PubMed ID: 27607159
[TBL] [Abstract][Full Text] [Related]
7. Value of 123I-MIBG Scintigraphy in Paraganglioma.
Milardovic R; Corssmit EP; Stokkel M
Neuroendocrinology; 2010; 91(1):94-100. PubMed ID: 19786729
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A
Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the diagnostic efficacy of whole-body MRI versus
Mori H; Wakabayashi H; Saito S; Nakajima K; Yoshida K; Hiromasa T; Kinuya S
Sci Rep; 2024 Jun; 14(1):13828. PubMed ID: 38879654
[TBL] [Abstract][Full Text] [Related]
11. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.
Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K
Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417
[TBL] [Abstract][Full Text] [Related]
12. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Comparative Study of 18 F-FDOPA PET/CT Versus 123 I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma.
Sung C; Lee HS; Lee DY; Kim YI; Kim JE; Lee SJ; Oh SJ; Sung TY; Lee YM; Kim YH; Kim BJ; Koh JM; Lee SH; Ryu JS
Clin Nucl Med; 2024 Jan; 49(1):27-36. PubMed ID: 38054497
[TBL] [Abstract][Full Text] [Related]
14. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
15. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
16. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial.
Vik TA; Pfluger T; Kadota R; Castel V; Tulchinsky M; Farto JC; Heiba S; Serafini A; Tumeh S; Khutoryansky N; Jacobson AF
Pediatr Blood Cancer; 2009 Jul; 52(7):784-90. PubMed ID: 19185008
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.
Chen L; Li F; Zhuang H; Jing H; Du Y; Zeng Z
J Nucl Med; 2009 Mar; 50(3):397-400. PubMed ID: 19223405
[TBL] [Abstract][Full Text] [Related]
18. Use of 131I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma.
Swensen SJ; Brown ML; Sheps SG; Sizemore GW; Gharib H; Grant CS; van Heerden JA
Mayo Clin Proc; 1985 May; 60(5):299-304. PubMed ID: 3990377
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
20. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
